Calculate Your Salary Ranking
Home > Neuralstem Salary

Neuralstem Salary
  • 53
  • 50
  • 98

Neuralstem average salary is $80,000, median salary is $80,000 with a salary range from $80,000 to $80,000.
Neuralstem salaries are collected from government agencies and companies. Each salary is associated with a real job position. Neuralstem salary statistics is not exclusive and is for reference only. They are presented "as is" and updated regularly.
Low
80,000
Average
80,000
Median
80,000
High
80,000
Total 1 Neuralstem Salaries. Sorted by Date, page 1
Ranked By:
Job Title Salaries City Year More Info
Pre-clinical Development, Senior Scientist 80,000-80,000 San Diego, CA, 92101 2012 Neuralstem Pre-clinical Development, Senior Scientist Salaries (1)
Neuralstem San Diego, CA Salaries
1
Calculate how much you could earn

It's FREE. Based on your input and our analysis.    How we do it?

All fields are required for calculation accuracy.

  • We will send you an email to access your personalized report.
  • We won’t share your email address
Recent Neuralstem Salaries (May 3, 2016)
Assistant Professor University of Oklahoma $42,860 Norman, OK, 73019 01/05/2015
General OMRON $65,998 Houston, TX, 77001 09/07/2015

Neuralstem salary is full-time annual starting salary. Intern, contractor and hourly pay scale vary from regular exempt employee. Compensation depends on work experience, job location, bonus, benefits and other factors.

Real Jobs Salary - Salary List
Neuralstem Information
  • Neuralstem, Inc
  • Industry: Biotech/Healthcare
  • City: Rockville, MD
  • Neuralstem's patent-protected technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia. The Company expects that its first Investigational New Drug (IND) application will be for the treatment of Ischemic Spastic Paraplegia, a form of paraplegia that sometimes results from the surgery to repair aortic aneurysms and for which there is no effective treatment. The Company hopes to submit its initial IND application to the FDA and begin its